Abstract

Pulmonary fibrosis is a hallmark of diseases such as systemic sclerosis (SSc, scleroderma) and idiopathic pulmonary fibrosis (IPF). To date, the therapeutic options for patients with pulmonary fibrosis are limited, and organ transplantation remains the most effective option. Insulin-like growth factor-binding protein 5 (IGFBP-5) is a conserved member of the IGFBP family of proteins that is overexpressed in SSc and IPF. In this study, we demonstrate that both exogenous and adenovirally expressed IGFBP-5 promote fibrosis by increasing the production of extracellular matrix (ECM) genes and the expression of pro-fibrotic genes in primary human lung fibroblasts. IGFBP-5 increased expression of the pro-fibrotic growth factor CTGF and levels of the matrix crosslinking enzyme lysyl oxidase (LOX). Silencing of IGFBP-5 had different effects in lung fibroblasts from normal donors and patients with SSc or IPF. Moreover, we show that IGFBP-5 increases expression of ECM genes, CTGF, and LOX in human lung tissues maintained in organ culture. Together, our data extend our previous findings and demonstrate that IGFBP-5 exerts its pro-fibrotic activity by directly inducing expression of ECM and pro-fibrotic genes. Further, IGFBP-5 promotes its own expression, generating a positive feedback loop. This suggests that IGFBP-5 likely acts in concert with other growth factors to drive fibrosis and tissue remodeling.

Highlights

  • Pulmonary fibrosis is a complication of several different diseases such as systemic sclerosis (SSc, scleroderma) and idiopathic pulmonary fibrosis (IPF)

  • We previously reported that Insulin-like growth factor-binding protein 5 (IGFBP-5) levels are increased in lung tissues of patients with IPF and primary fibroblasts derived from those lung tissues [12]

  • We show that Insulin-like growth factor-binding proteins (IGFBPs)-5 expression is significantly elevated in lung tissues (Figure 1A) and matching primary fibroblasts (Figure 1B) from patients with SScassociated lung disease

Read more

Summary

Introduction

Pulmonary fibrosis is a complication of several different diseases such as systemic sclerosis (SSc, scleroderma) and idiopathic pulmonary fibrosis (IPF). SSc-associated lung disease has become the leading cause of death in scleroderma patients [2, 3]. IPF and SSc, while being different diseases, show some similarities [4, 5]. Pulmonary fibrosis in both of these diseases is characterized by the overproduction of extracellular matrix (ECM) components in the lung. The therapeutic options for patients with pulmonary fibrosis are limited, and lung transplantation remains the most effective treatment [2]. Identifying novel therapeutic targets would significantly advance the treatment of IPF and SSc-associated lung disease

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call